Navigation Links
GeoVax Labs Engages The Investor Relations Group
Date:3/22/2010

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents.  Our goals include developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting human trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.  All preventative phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA AIDS vaccines in human volunteers for their demonstrated ability to raise anti-HIV immune responses as well as for their safety.  Successful results from all phase 1 testing supported the initiation of the first phase 2 testing.  GeoVax's phase 2 human trial began in January 2009 and will involve 225 participants at sites in the United States and South America.  Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues.  Internal vaccine manufacturing and distribution will also be considered by GeoVax.  For more information, please visit www.geovax.com.

About The Investor Relations Group, Inc.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
2. GeoVax Labs, Inc. Plans Public Offering
3. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
6. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
7. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
8. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. GeoVax Reports Progress on Its AIDS Vaccine Technology
11. GeoVax Secures $10 Million Financing Commitment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has announced ... Global Trends, Estimates and Forecasts, 2012-2018" report to ... Global Electrocardiogram Devices (ECG) sector is projected ... North America accounts for nearly 36% (2015) ... claims approximately 27% (2018). Asia-Pacific ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... no additional very late stent thrombosis, NATICK, ... Corporation (NYSE: BSX ) today announced five-year ... demonstrating continued,long-term safety and efficacy for the TAXUS(R) ... showed no additional stent,thrombosis between years four and ...
... Aug. 30 ViroPharma Incorporated,(Nasdaq: VPHM ) today ... financial officer of ViroPharma, will present,at the Thomas Weisel ... September 5, 2007. The conference is being held at ... will also present at the 14th Annual BioCentury Newsmakers,in ...
Cached Medicine Technology:Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 2Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 3Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 4ViroPharma to Present at Three Upcoming Healthcare Conferences 2
(Date:12/15/2014)... December 15, 2014 Cancer researchers have ... underlying genetic causes of deadly malignant pleural mesothelioma. Surviving ... on their website. Click here to read it ... of Hawaii Cancer Center, and New York’s Langone Medical ... pleural mesothelioma patients in an effort to pinpoint ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... 2014 In support of high-quality ... to restrictive state laws that may have unintended ... important area of public health policy. , The ... Integrity of Independent Review, contends that state legislation ... peer review determinations can result in subpar outcomes ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... Reporter , MONDAY, Sept. 27 (HealthDay News) -- Implantable ... of thousands of Americans at risk for sudden cardiac ... these medical devices have gotten a bad reputation in ... that connect the ICD to the heart can sometimes ...
... Australia and Hong Kong have conducted a comprehensive study ... of female attractiveness. The study, published in the ... divides young, tall and long armed women were considered ... important determining factor for evolutionary, social and economic success," ...
... their international colleagues have discovered genetic variants that lead ... taking aromatase inhibitors to treat their breast cancer. This ... halt their lifesaving medication. The findings appear today in ... . "Many women stop taking aromatase inhibitors due ...
... HealthDay Reporter , MONDAY, Sept. 27 (HealthDay News) -- ... risk of dying in the hospital and help their doctors ... Hospitals also can use the prediction tool to ... Eric Smith, assistant professor of neurology at the University of ...
... Onconova Therapeutics, Inc. is presenting new data in ... several studies with the company,s radioprotectant Ex-RAD at the ... September 25-29 in Maui, Hawaii. In vivo studies ... increase in survival versus placebo-treated groups in mice exposed ...
... place Jan. 13-16, 2011 at the Wynn Las Vegas. ... (each morning), observing differences in technique from a variety ... Lectures and plenary sessions will cover topics as bladder, ... to treat patients with benign prostate cancer. , Also ...
Cached Medicine News:Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 2Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 3Health News:Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies 2Health News:Mayo collaboration finds source of breast drug side effect 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 3Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: